Latest | Instant news on finance, ETFs, IPOs etc. _第119页 | NewTimeSpace

22:14

【E&P GLOBAL(01142.HK): Appeal in Russian Mining Licence Litigation Dismissed; Original Ruling Upheld】NewTimeSpace News: E&P Global Holdings Limited (01142.HK) announced that the ruling rendered by the Moscow City Arbitration Court on 15 April 2026 remains unchanged, and the appeal filed by relevant Russian authorities has been dismissed. The appellate court is expected to hand down its summary judgement by 7 August 2026.

Tag： E&P GLOBAL 01142.HK dismiss an appeal

21:37

【VIRTUAL MIND(01520.HK): Memorandum Signed with Saudi Rasiaph Art Institution to Expand Middle‑East Art IP Business】NewTimeSpace News: Virtual Mind (01520.HK) announced that it signed a memorandum of understanding for cooperation with Saudi‑Arabia‑based Rasiaph Art Production Institution on 3 August 2026. Both parties intend to carry out global cooperation on art‑IP business covering core areas including exhibition organisation, artwork‑business expansion and artwork digitisation.

Tag： VIRTUAL MIND 01520.HK memorandum of understanding IP

21:27

【BONJOUR HOLD(00653.HK): Strategic Cooperation Launched with Hong Kong Yuncang Daji, Target Turnover of HK$30‑Million for the Year】NewTimeSpace News: Bonjour Holdings Limited (00653.HK) announced that following the strategic‑cooperation agreement signed on 13 July 2026, the Group officially held the launching ceremony themed “Sailing Overseas, Mutual Pursuit” on 30 July, moving the partnership with Hong Kong Yuncang Daji Development Company Limited from strategic consensus to substantive market‑expansion phase. Yuncang, as the operating entity, is set with a turnover target of HK$30 million for the period ending 31 December 2026.

Tag： BONJOUR HOLD 00653.HK strategic cooperation

21:22

【AUTO ITALIA(00720.HK): Subsidiary Signs Automobile Sales Contract Worth Approximately EUR3.46 Million】NewTimeSpace News: Auto Italia Holdings Limited (00720.HK) announced that its indirectly wholly‑owned subsidiary Handerson Auto Import and Export (Chongqing) Co., Limited has entered into a sales contract with Fabrika Poljoprivredne Mehanizacije Agromehanika D.O.O. Boljevac for the sale of Euro‑eBOLD‑model vehicles, with an aggregate contract value of approximately EUR3.46 million.

Tag： AUTO ITALIA 00720.HK sales contract

21:14

【Hangzhou Yodosmart Automotive Technology Co., Ltd.: 4G T‑Box Shipment Volume Ranks 3rd Domestically! Yodosmart Resubmits HKEX IPO Application】NewTimeSpace News: Hangzhou Yodosmart Automotive Technology Co., Ltd. resubmitted its IPO application to HKEX on 4 August 2026, with China International Capital Corporation (CICC) acting as the sole sponsor. According to Frost & Sullivan reports, the Company is a leading domestic supplier of automotive intelligent‑connected solutions in China. By shipment volume of 4G T‑Box in 2025, it ranks third among domestic suppliers and fourth among all suppliers, with a 5.2% market share. It is the second‑largest domestic supplier of emergency‑call terminals by shipment volume, holding a 2.6% market share.

Tag： Yodosmart IPO file a listing application

20:01

【SUNHO BIO‑B(02898.HK): Appoints ZZ Risk Management as Independent Internal Control Consultant; Shares Remain Suspended】NewTimeSpace News: Sunho Biologics, Inc.(02898.HK) announced that upon the recommendation of the Audit Committee, the Company has appointed ZZ Risk Management Consulting Services Limited as its independent internal‑control consultant on 4 August 2026 to conduct an independent internal‑control review covering key areas including financial reporting, cash management and connected‑party transaction disclosure.

Tag： SUNHO BIO-B 02898.HK suspended from trading

19:56

【DAJIN (01081.HK): Shipbuilding Contract for Two Bulk Carriers Signed with Norwegian Ship‑owner, Total Value Approximately RMB1.0 Billion】NewTimeSpace News: Dajin Heavy Industry Co., Ltd. (01081.HK) announced that its subsidiary Tangshan Dajin Offshore Engineering Co., Ltd. has entered into a shipbuilding contract for two bulk carriers with a Norwegian ship‑owner. The vessels are 211,000 DWT bulk carriers with an aggregate contract value of approximately RMB1.0 billion, to be delivered in batches in 2029.

Tag： DAJIN 01081.HK Business Contract

19:20

【RAFFLESINTERIOR(01376.HK): Independent Investigation Uncovers Material Irregularities; Former Executive Director Allegedly Signed HK$300‑Million Acquisition Without Authorisation, Spousal Connected‑Party Transaction Suspected of Generating HK$288‑Million 】NewTimeSpace News: Raffles Interior Limited (01376.HK) announced key interim findings from an independent investigation. The investigation uncovered that former Executive Director Mr. Zheng Nenghuan unilaterally signed an acquisition agreement on behalf of the Company at a consideration of HK$300 million on 3 November 2025 without Board authorisation, for assets beneficially owned by his spouse Ms. Tang Judi. The assets were acquired for RMB10 million and resold to the Company at HK$300 million merely five weeks later, raising suspicions of benefit transfer and material concealment. The Board expressed serious concerns regarding his integrity and suitability to act in a director capacity.

Tag： 01376.HK RAFFLESINTERIOR independent investigation

19:09

【LEADS BIOLABS-B(09887.HK): Partner Oblenio Bio Completes First‑in‑Human Phase Ia First‑Patient Dosing of LBL‑051 for Refractory Autoimmune Diseases】NewTimeSpace News: Nanjing Leads Biolabs Co., Ltd. (09887.HK) announced that Oblenio Bio, the joint venture established with Aditum Bio, has completed first‑patient dosing in the Phase Ia first‑in‑human clinical trial of LBL‑051, a trispecific T‑cell engager targeting BCMA, CD19 and CD3. Pre‑clinical data demonstrated that LBL‑051 could achieve complete depletion of B‑cells and plasma cells via co‑targeting CD19 and BCMA with minimal cytokine release.

Tag： LEADS BIOLABS-B 09887.HK Clinical Trial

18:31

【HENGRUI PHARMA(01276.HK): SHR‑A2009 for Injection Combined with Adebrelimab Obtains NMPA Clinical Trial Approval for Non‑Small‑Cell Lung Cancer】NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (01276.HK) announced that its subsidiaries have received the Drug Clinical Trial Approval Notice ratified and issued by NMPA. Phase II clinical trials are approved to evaluate SHR‑A2009 for Injection (HER3‑targeted ADC) in combination with adebrelimab, or in combination with third‑generation EGFR TKI, among patients with non‑small‑cell lung cancer. To date, no HER3‑targeted ADC has been approved globally for the treatment of NSCLC.

Tag： HENGRUI PHARMA 01276.HK Clinical Trial

18:25

【SEYOND(02665.HK): Memorandum of Strategic Cooperation Signed with Plus.ai to Jointly Promote L4 Autonomous Freight and Physical AI Implementation】NewTimeSpace News: Seeyond Holdings Ltd. (02665.HK) announced that its wholly‑owned subsidiary Seeyond Suzhou has signed a memorandum of strategic cooperation with Plus.ai. The two parties will cooperate across three major areas: L4‑level autonomous freight and RoboVan, physical AI and data application, as well as smart logistics infrastructure, so as to drive the intelligent upgrading of trunk‑line logistics and autonomous freight transportation.

Tag： SEYOND 02665.HK strategic cooperation

18:20

【BASIC SEMI(09971.HK): Strategic Cooperation Reached with Episil Technologies to Accelerate Development and Mass‑Production of 8‑inch SiC Wafers】NewTimeSpace News: BASiC Semiconductor Co., Ltd. (09971.HK) announced that it has entered into a strategic cooperation with Episil Technologies on 4 August 2026. Building on their long‑term prior collaboration, both parties will speed up the development and mass‑production of 8‑inch silicon carbide (SiC) wafers, jointly advance new‑process platform development, and expand the market share of SiC products in sectors such as new‑energy vehicles and AI computing centres.

Tag： BASIC SEMI 09971.HK strategic cooperation Episil Tech

18:12

【CSPC PHARMA(01093.HK): NDA for Neoadjuvant Therapy of Anitumab Combined with HB1801 in HER2‑positive Breast Cancer Accepted and Granted Priority Review】NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the New Drug Application for neoadjuvant therapy of Anitumab (KN026) co‑developed with Alphamab Oncology in combination with the Group’s self‑developed Docetaxel (Albumin‑Bound) for Injection (HB1801) for adult patients with early or locally advanced HER2‑positive breast cancer has been accepted by NMPA and included in the priority review and approval procedure. A pivotal Phase III study demonstrated that the combination regimen significantly improved the overall pathological complete response rate versus current standard‑of‑care treatment.

Tag： CSPC PHARMA 01093.HK ALPHAMAB-B New Drug Application

17:54

【CHINASHENGMU‑PF(01432.HK): Addition of "PF" Suffix to Stock Short Name Due to Severe Shortfall in Public Float】NewTimeSpace News: China Shengmu Organic Milk Limited (01432.HK) announced that due to non‑compliance with the minimum public float requirement under Listing Rule 13.32B and the condition of severe shortfall in public float under Listing Rule 13.32F, the stock short name will be changed to “CHINASHENGMU‑PF” in English and “中国圣牧‑PF” in Chinese, effective from 9:00 a.m. on 5 August 2026. The stock code “1432” remains unchanged. The suffix will be removed once the Company re‑complies with relevant requirements.

Tag： CHINASHENGMU‑PF 01432.HK Public Float

17:38

【Liu Chong Hing Investment (00194.HK): Appoints Zeng dian ke as Executive Director】NewTimeSpace News: Liu Chong Hing Investment announced on August 4 that Zeng dian ke , Co-Chief Executive Officer of the Company, has been appointed by the Board as Executive Director, effective 4 August 2026.

Tag： Liu Chong Hing Investment 00194.HK

17:32

【HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China】NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that its self‑developed candidate HX9428 has obtained US‑FDA IND clearance to commence Phase II clinical trial for neovascular age‑related macular degeneration (nAMD). Meanwhile, the Company has officially launched its second Phase II clinical study (CTR20262884) of HX9428 for nAMD in China, adopting a head‑to‑head positive‑control design against aflibercept.

Tag： HAIXI PHARMA 02637.HK Clinical Trial

17:28

【ALLAN INTERNATIONAL HOLDINGS (00684.HK): Public Float Still Below 25%, Recovery Plan Expected to Be Formulated Before End of Q3】NewTimeSpace News: ALLAN INTERNATIONAL HOLDINGS announced on August 4 that as at the date of the announcement, the company’s public float stood at 24.04%, still below the minimum 25% requirement stipulated under the Listing Rules. The Board is considering adopting a share scheme and expects to formulate a detailed recovery plan before the end of the third quarter of 2026.

Tag： ALLAN INTERNATIONAL HOLDINGS 00684.HK

17:21

【Changan Minsheng Logistic (01292.HK): Expected Net Profit for First Half to Drop by Approximately 39.73% to 51.78% Year-on-Year】NewTimeSpace News: Changan Minsheng Logistic announced on August 4 that for the six months ended 30 June 2026, revenue is expected to range from RMB4.45 billion to RMB4.6 billion, representing a year-on-year increase of roughly 6.89% to 10.5%; net profit attributable to owners of the Company is projected at RMB20 million to RMB25 million, a year-on-year decrease of approximately 39.73% to 51.78%.

Tag： Changan Minsheng Logistic 01292.HK

17:16

【TRULY INT'L (00732.HK): Unaudited July Turnover Approximately HK$1.259 Billion, Down 14.2% YoY】NewTimeSpace News: Truly International Holdings Limited (00732.HK) announced that the Group’s unaudited consolidated net turnover for July 2026 stood at approximately HK$1.259 billion, representing a decrease of around 14.2% compared with HK$1.468 billion for the corresponding period in 2025. For the seven‑month period ended 31 July, cumulative consolidated net turnover totalled approximately HK$8.224 billion, a drop of roughly 14% versus HK$9.566 billion in the same period of last year.

Tag： TRULY INT 00732.HK decline in performance

17:12

【SKYWORTH GROUP (00751.HK): Expected Unaudited Profit After Tax for First Half to Rise by No Less Than 170% Year-on-Year】NewTimeSpace News: SKYWORTH GROUP announced on August 4 that the unaudited profit after tax for the six months ended 30 June 2026 is expected to increase by no less than 170% compared with the same period last year.

Tag： SKYWORTH GROUP 00751.HK

Scan QR Code

Download App